Search Tag: pharmacovigilance
2026 30 Mar
Drug–drug interactions (DDIs) occur when co-administered medicines alter each other’s pharmacological or clinical effects, influencing therapeutic efficacy and patient safety. DDIs are typically classified as pharmaceutical, pharmacokinetic or pharmacodynamic interactions. Combination therapies are widely used in areas such as oncology and ca1Read more
2026 30 Mar
Drug–drug interactions (DDIs) occur when co-administered medicines alter each other’s pharmacological or clinical effects, influencing therapeutic efficacy and patient safety. DDIs are typically classified as pharmaceutical, pharmacokinetic or pharmacodynamic interactions. Combination therapies are widely used in areas such as oncology and ca1Read more
2026 30 Mar
Drug–drug interactions (DDIs) occur when co-administered medicines alter each other’s pharmacological or clinical effects, influencing therapeutic efficacy and patient safety. DDIs are typically classified as pharmaceutical, pharmacokinetic or pharmacodynamic interactions. Combination therapies are widely used in areas such as oncology and ca1Read more
2020 12 Dec
As the world's first COVID-19 mass vaccination programmes are underway in the UK, the U.S. and some other countries, a new paper (Vander Stichele et al. 2020) highlights the need for global monitoring of vaccine use (who was inoculated with which vaccine product, where and when) as well as its safety and effectiveness. You migh1Read more
2014 19 Sep
A new report from Escher, the independent TI Pharma platform for regulatory innovation, shows that the current regulatory system for medicines in Europe can be used in a more efficient and effective manner. André Broekmans, chairman of Escher: “ Overall, the EU regulatory system operates well, however important recent changes had not yet been1Read more